Objectives. Epidemiology. Pathophysiology 4/1/2013
|
|
- Norma Craig
- 8 years ago
- Views:
Transcription
1 Objectives The New CHEST Guidelines, The Bleeding War Continues Ginger Warren, PharmD., MCSR PGY1 Pharmacy Resident Valley Health System/Bernard J Dunn School of Pharmacy, Shenandoah University April 3 rd, 2013 I have no relevant financial relationships or interests to declare Identify updates/changes in the atrial fibrillation (AF) chapter of the 9 th edition CHEST guideline Choose an appropriate treatment course for a patient based on a CHADS 2 score Recognize strong recommendations as compared to those with weak evidence Select appropriate counseling points for a patient starting on one of the new agents used in atrial fibrillation Epidemiology Pathophysiology Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia 1 Affects almost 3 million people in the United States 1 Prevalence increases with age 1 Approximately 9% of patients 80 years old In 2005, estimated cost of treatment per year including hospitalizations was $6.65 billion 2 Risk of ischemic stroke w/o thromboprophylaxis is 5% per year Shortened action potential & refractory period rapid atrial rate 1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114(7):e , 2. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health Sep Oct;9(5):
2 Stroke Risk Stratification Risk Factor (CHADS 2 ) PointValue Congestive heart failure/lv dysfunction 1 Hypertension 1 Age 75 years old (yo) 1 Diabetes mellitus 1 Prior history of Stoke or transient ischemic attack 2 Risk Factor (CHADS 2 VASc) Point Value Congestive heart failure/lv dysfunction 1 Hypertension 1 Age 75 yo 2 Diabetes mellitus 1 Prior history of Stoke or transient ischemic attack 2 Vascular Disease 1 Age yo 1 Female Sex 1 Ischemic Stroke and Systemic Embolism Risk Factor Relative Risk Congestive heart failure 1.4 History of hypertension 1.6 Advanced age (continuous, per decade) 1.4 Diabetes mellitus 1.7 Previous stroke or TIA 2.5 Fuster V, et al. J Am Coll Cardiol 2006;48:e149 e246. Gage BF, et al. JAMA 2001;285: Antithrombotic Therapy and Prevention of Thrombosis, 9 th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines Chapter 18: Antithrombotic Therapy for Atrial Fibrillation Level of Evidence Outlines prevention, diagnosis, & treatment of thrombosis Encompasses many clinical conditions: medical surgery, orthopedic surgery, atrial fibrillation, stroke, cardiovascular disease, pregnancy, children, etc. Includes > 600 recommendations in > 800 pages Strong grade 1 Weak grade 2 High quality A Moderate quality B Low quality C Guyatt GH, Akl EA, Crowther M, et al. Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):48S 52S. photo/strong.html, 2
3 Antithrombotic Therapy and Prevention of Thrombosis, 9 th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines Chapter 18: Antithrombotic Therapy for Atrial Fibrillation Decision Pathway Start here Atrial fibrillation Patients included: Permanent, persistent, or paroxysmal AF Special situations Cardioversion Patients NOT included: Pre & postinvasive procedures Acute stroke Prosthetic valve Pregnant Single, isolated episode CHADS 2 = 0: No therapy No CAD CHADS 2 1: anticoagulation No mitral stenosis CHADS 2 = 0: patient specific therapy Stable CAD CAD CHADS 2 1: VKA monotherapy Mitral stenosis VKA therapy ACS w/n 12 mths To be continued Low Risk Data for CHADS 2 = 0 No therapy > Antithrombotic therapy Alternatives Aspirin > Oral anticoagulation Aspirin > Aspirin + clopidogrel Grade 2B Grade 2B Grade 2B ASA use for 1 year compared to no treatment prevented 2 nonfatal strokes while causing 3 nonfatal major extracranial bleeds per 1000 patients Use of VKA therapy compared to no therapy resulted in 5 fewer nonfatal strokes and 8 more nonfatal major extracranial bleeds per 1000 patients Reduction in all cause mortality not likely to extend to low risk patients Increased risk for intracranial hemorrhage remains similar to higher risk patients Oral anticoagulation may be favored for patients with multiple non CHADS 2 risk factors for stroke (age 65 74, female sex, vascular disease, etc.) 3
4 Intermediate Risk Dabigatran versus warfarin in patients with atrial fibrillation Randomized Evaluation of Long term anticoagulant therapy (RE LY) trial CHADS 2 = 1 Oral anticoagulation* > No therapy Grade 1B > Aspirin Grade 2B > Aspirin + clopidogrel Grade 2B Alternative (for reasons other than bleeding concerns) Aspirin + clopidogrel > Aspirin Grade 2B Randomized, multicenter, prospective, noninferiority trial dabigatran 110 mg bid or 150 mg bid versus warfarin in patients with nonvalvular AF and 1 of the following: Previous stroke or transient ischemic attack (TIA) Left ventricular ejection fraction (LVEF) < 40% CHF, NYHA class 2 Age 75 yo Age yo with DM, CAD, HTN Primary efficacy outcome: stroke or systemic embolism *Oral anticoagulation Dabigatran 150mg twice daily > Warfarin Grade 2B Primary safety outcome: major hemorrhage Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): Dabigatran versus warfarin in patients with atrial fibrillation Randomized Evaluation of Long term anticoagulant therapy (RE LY) trial High Risk Results listed as % of patients per year: Event Warfarin (n = 6022) *p < 0.05 compared to warfarin **p < 0.05 compared to dabigatran 150 mg Dabigatran 110 mg (n = 6015) Dabigatran 150 mg (n = 6076) Stroke/systemic embolism * 1.11* Ischemic stroke * Hemorrhagic stroke * 0.1* Major bleed * 3.11 Gastrointestinal (GI) bleed 1.02** Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): CHADS 2 2 Oral anticoagulation* > No therapy Grade 1A > Aspirin Grade 1B > Aspirin + clopidogrel Grade 1B Alternative (for reasons other than bleeding concerns) Aspirin + clopidogrel > Aspirin Grade 1B *Oral anticoagulation Dabigatran 150mg twice daily > Warfarin Grade 2B 4
5 Data for Question VKA therapy compared to ASA for 1 year resulted in 19 fewer strokes at the expense of 3 more bleeds per 1000 patients VKA therapy compared to ASA + clopidogrel for 1 year resulted in 11 fewer strokes and up to 3 more bleeds per 1000 patients Dual antiplatelet therapy is inferior as compared to VKA therapy for stroke prevention 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest Feb;141(2 Suppl):e531S 75S., ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet Jun 10;367(9526): Which of the following has been shown to be associated with an increased stroke risk that is identified in CHADS 2 VASc? A) Female sex B) Age yo C) Asian race D) Valvular disease Case Case, part 2 GB is a 67 yo female with atrial fibrillation, rhythm controlled with amiodarone 200 mg daily. Her PMH is significant for migraines, gestational DM, and endometriosis. What is her CHADS 2 score? A) 0 B) 1 C) 2 D) 3 GB is a 67 yo female atrial fibrillation, rhythm controlled with amiodarone 200 mg daily. Her PMH is significant for migraines, gestational DM, and endometriosis. Based on GB s CHADS 2 score, what is the recommended antithrombotic therapy? A) no pharmacological agent B) aspirin 75 mg 325 mg daily C) dose adjusted warfarin with goal INR 2 3 D) aspirin 75 mg 325 mg daily + clopidogrel 75 mg daily 5
6 Decision Pathway ACS w/n 12 mths Special Situations No stent placement Stent placement CHADS 2 = 0: dual antiplatelet therapy x 12 mths CHADS 2 1: VKA therapy + antiplatelet x 12 mths Bare metal Drug eluting CHADS 2 1: ASA + clopidogrel x 12 mths CHADS 2 2: triple therapy x 1 mth CHADS 2 1: ASA + clopidogrel x 12 mths CHADS 2 2: triple therapy x 3 6 mths VKA therapy + antiplatelet x 2 nd 12 th mth VKA therapy + antiplatelet x > 3 6 mths 12 th mth Reassess antithrombotic therapy needs after completion of 12 mths = Stable CAD AF + Mitral Stenosis AF + Stable Coronary Artery Disease CHADS 2 0 Oral anticoagulation* > No therapy Grade 1B > Aspirin Grade 1B > Aspirin + clopidogrel Grade 1B Alternative (for reasons other than bleeding concerns) Aspirin + clopidogrel > Aspirin Grade 1B Patients with coronary artery disease (CAD) are recommended to use ASA for prevention of cardiovascular events 1/3 of AF patients have CAD CHADS 2 0 Warfarin > Warfarin + aspirin Grace 2C *Oral anticoagulation Warfarin 6
7 AF + Non invasive ACS Low or Intermediate Risk + Stent CHADS 2 1 First 12 months after ACS Warfarin + antiplatelet agent > Aspirin + clopidogrel Grace 2C > Warfarin + aspirin + clopidogrel Grade 2C > 12 months after ACS* Warfarin > Warfarin + aspirin Grace 2C *same recommendation as AF + Stable CAD CHADS 2 = 0 1 First 12 months post bare metal OR drug eluting Aspirin + clopidogrel > Warfarin + aspirin + clopidogrel Grade 2C >Warfarin + aspirin Grade 2C > 12 months* Warfarin >Warfarin + aspirin Grade 2C *same recommendation as AF + Stable CAD High Risk + Stent AF + Elective Cardioversion CHADS 2 2 Bare metal: 1 st month Drug eluting: First 3 6 months Warfarin + aspirin + clopidogrel > Aspirin + clopidogrel Bare metal: 2 nd 12 th month Drug eluting: > 3 6 months 12 th month Warfarin + antiplatelet agent > Warfarin Bare metal: > 12 months* Drug eluting: > 12 months* Warfarin > Warfarin + aspirin *same recommendation as AF + Stable CAD Grade 2C Grade 2C Grade 2C AF > 48 hours Before scheduled cardioversion Warfarin, LMWH, or dabigatran x 3 weeks > No therapy After successful cardioversion Warfarin, LMWH, or dabigatran x 4 weeks > No therapy AF 48 hours Before cardioversion LMWH or UFH > Delaying 3 weeks for anticoagulation After successful cardioversion Warfarin, LMWH, or dabigatran x 4 weeks > No therapy 1B 1B 2C 2C 7
8 AF + Immediate Cardioversion Case Before cardioversion Parenteral anticoagulation >No therapy* 2C After successful cardioversion Warfarin, LMWH, or dabigatran x 4 weeks > No therapy 2C *do not delay intervention for initiation of anticoagulation LW is a 78 yo female with atrial fibrillation, rate controlled with metoprolol tartrate 25 mg bid. Her PMH is significant for hypertension, MI in 2008, and asthma. Based on LW s CHADS 2 score, what is the recommended antithrombotic therapy? A) aspirin 75 mg 325 mg daily B) dose adjusted warfarin with goal INR 2 3 C) aspirin 75 mg 325 mg daily + clopidogrel 75 mg daily D) dabigatran 150 mg twice daily Case, part 2 If LW s MI was 11/12 with bare metal stenting, would the recommendation change? A) Yes, dose adjusted warfarin with goal INR aspirin 75 mg 325 mg daily + clopidogrel 75 mg daily B) Yes, dose adjusted warfarin with goal INR aspirin 75 mg 325 mg daily OR dose adjusted warfarin with goal INR clopidogrel 75 mg daily C) No D) Yes, dabigatran 150 mg twice daily + aspirin 75 mg 325 mg daily New Oral Anticoagulants 8
9 The Ideal Anticoagulant Rivaroxaban (Xarelto ) Direct Factor Xa inhibitor Available and effective antidote Low cost Wide therapeutic index Quick onset Minimal drug interactions Once daily dosing Oral Minimal monitoring FDA Indications: Postoperative thromboprophylaxis Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE) Prevention of stroke & systemic embolism in nonvalvular AF Dose: 20 mg daily with evening meal Pharmacokinetics: Absorption: bioavailability %, take with food for AF indication Metabolism: P glycoprotein, CYP3A4 substrate Elimination: half life of 5 9 h, h (elderly); 66% (renal), 34% (feces) Avoid use in CrCl < 15 ml/min Dose reduction for CrCl ml/min Rivaroxaban. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com Rivaroxaban (Xarelto ) Direct Factor Xa inhibitor Rivaroxaban (Xarelto ) Direct Factor Xa inhibitor Contraindications/Warnings: Box Warnings: Neuraxial anesthesia or spinal puncture Discontinuation of therapy Hepatic disease Active bleeding Concomitant use with strong CYP3A4 or P glycoprotein inhibitors/inducers Monitoring: routine monitoring not required Anti factor Xa no therapeutic level has been established Prothrombin time (PT)/ INR dose dependent with PT; INR is standardized for warfarin Activated partial thromboplastin time (aptt) not effective, prolongation only seen at peak drug levels Rivaroxaban. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com Common adverse effects: Bleeding (hip/knee replacement 5.8% ) Serious adverse effects: Syncope (1.2% ) GI hemorrhage (3.1% ) Major bleeding (a fib 5.6%; hip/knee 0.3% ) Epidural/spinal hematoma Anaphylaxis Cerebrovascular accident Rivaroxaban. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com, Patient Instructions: Do not miss doses Take with evening meal 9
10 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) Randomized, multicenter, double blind, double dummy, prospective, noninferior trial of rivaroxaban 20 mg daily vs warfarin in patients with nonvalvular AF & history of stroke, TIA, or systemic embolism or 2 of the following: LVEF 35% or CHF HTN Age 75 yo DM Primary efficacy outcome: stroke or systemic embolism Primary safety outcome: major or nonmajor clinically relevant bleeding events Results listed as number of events per 100 patient years: Events Warfarin (n = 7004) Rivaroxaban (n = 6958) Stroke/systemic embolism * Ischemic stroke Hemorrhagic stroke * Major bleed GI bleed (listed as %) 2.16** 3.15 *p < 0.05 compared to warfarin **p < 0.05 compared to rivaroxaban Patel MR, Mahaffey KW, Garg J, Pan G, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10): Patel MR, Mahaffey KW, Garg J, Pan G, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10): Dabigatran (Pradaxa ) Direct thrombin inhibitor Dabigatran (Pradaxa ) Direct thrombin inhibitor FDA indications: Postoperative thromboprophylaxis Prevention of stroke &systemic embolism in nonvalvular AF Dose: 150 mg twice daily Pharmacokinetics: Absorption: bioavailability 3 7%; take with or without food Metabolism: P glycoprotein; converted to active moiety by esterasecatalyzed hydrolysis Elimination: half life of h; 80% (renal) Avoid use in CrCl < 15 ml/min Dose reduction for CrCl ml/min Dabigatran. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com Contraindications/Warnings: Active bleeding Prosthetic heart valve Elderly population Discontinuation of therapy Concomitant use with strong P glycoprotein inhibitors/inducers Monitoring: routine monitoring not required aptt value 2.5 x normal may indicate over anticoagulation Dabigatran. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com 10
11 Dabigatran (Pradaxa ) Direct thrombin inhibitor Dabigatran (Pradaxa ) Direct thrombin inhibitor Common adverse effects: Esophagitis, GERD, GI hemorrhage (6.1% ) Bleeding (16.6% ) Serious adverse effects: Major GI hemorrhage (1.6% ) Life threatening bleeding (1.5% ) Major bleeding (3.3% ) Anaphylaxis (< 0.1% ) Intracranial hemorrhage (0.3% ) Dabigatran. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com Patient instructions: Do not miss doses Do not break capsule Keep medication in original bottle Discard medication 120 days after opening bottle Dabigatran. Clinical Pharmacology. Retrieved Jan 5, 2013 from clinical pharmacology.com, Apixaban (Eliquis ) Direct Factor Xa inhibitor Apixaban (Eliquis ) Direct Factor Xa inhibitor FDA approved indication: Prevention of stroke or systemic embolism in nonvalvular AF Dose: 5 mg twice daily 2.5 mg twice daily if 2 of the following: age 80 yo, weight 60 kg, SCr 1.5 mg/dl Pharmacokinetics: Absorption: bioavailability ~50%; take with or without food Metabolism: P glycoprotein; CYP3A4 substrate (minor) Elimination: half life 12 h; 25% (renal), 55% (feces) Avoid use in CrCl < 15 ml/min Apixaban. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com Contraindications/Warnings: Active bleeding Prosthetic heart valve Hepatic disease Body weight < 50 kg or > 120 kg Neuraxial anesthesia Monitoring: routine monitoring not required PT/INR prolonged aptt prolonged Anti factor Xa linear relationship with plasma concentrations Apixaban. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com 11
12 Apixaban (Eliquis ) Direct Factor Xa inhibitor Apixaban versus warfain in patients with atrial fibrillation Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation trial (ARISTOTLE) Common adverse effects: Bleeding (6%) Nausea (7%) Vomiting (5%) Constipation (5%) Serious adverse effects: Major bleeding (2.1% ) Anaphylaxis (< 1% ) Intracranial hemorrhage (0.3% ) Patient Instructions: Do not miss doses Randomized, multicenter, double blind, double dummy, prospective, noninferior trial of apixaban 5 mg bid vs warfarin in patients with nonvalvular AF and 1 of the following: Previous stroke, TIA, or systemic embolism LVEF 40% or symptomatic CHF w/n 3mos HTN requiring medication management Age 75 yo DM Primary efficacy outcome: stroke or systemic embolism Primary safety outcome: major bleed Apixaban. Clinical Pharmacology. Retrieved Jan 5, 2013 from clinicalpharmacology.com, receivesresubmission apixaban drug application reduce stroke patients atrial fibrillati Granger CB, Alexander JH, McMurray JJ, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): Apixaban versus warfain in patients with atrial fibrillation Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation trial (ARISTOTLE) Question Results listed as % of patients per year: Events Warfarin (n = 9081) Apixaban (n = 9120) Stroke/systemic embolism * Ischemic stroke Hemorrhagic stroke * Major bleed * GI bleed Which of the new oral anticoagulants must be taken with food? A) Rivaroxaban B) Dabigatran C) Apixaban D) All of the above *p < 0.05 compared to warfarin Granger CB, Alexander JH, McMurray JJ, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):
13 Question Comparison of Oral Anticoagulants Dabigatran should be dispensed in the original bottle and should be discarded after how many months? A) 1 B) 2 C) 3 D) 4 Rivaroxaban. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com, Dabigatran. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com, Apixaban. Clinical Pharmacology. Retreived Jan 5, 2013 from clinicalpharmacology.com Challenges with New Agents Case Bleeding concern Lack of antidote Cost of reversal and prolonged length of hospitalization Little experience with use in special populations: obesity, renal dysfunction, liver dysfunction, pediatric patients, etc. Little knowledge of concomitant use with dual antiplatelet agents GW is a 72 yo female with atrial fibrillation, rate controlled on metoprolol succinate 25mg daily, hypertension, COPD, and h/o ischemic stroke She is taking dabigatran 150 mg twice daily and minor GI bleeding with continued use. She wonders is she should try a different food to sprinkle the medication on besides applesauce. Any suggestions? A) Switch GW to adjusted dose warfarin goal INR 2 3 B) Recommend to sprinkle on yogurt C) Recommend to not sprinkle on any food but take the capsule whole D) Recommend to continue to sprinkle on applesauce and add a PPI to her medication regimen 13
14 Conclusions The recommendation for low risk AF patients is no antithrombotic therapy The recommendation for CHADS 2 score 1 is dabigatran 150 mg twice daily for patients without CAD and with similarities to those in the RE LY trial Patients with stable CAD on warfarin therapy are not recommended to add ASA to their regimen Rivaroxaban must be taken with food and is once daily while dabigatran and apixaban are twice daily and may be taken with or without food Questions gwarren@valleyhealthlink.com To obtain credit for this CE Sign in and attend entire live activity Register using link from or address below: pharmacy.su.edu/cpe Complete online post test scoring 70% plus online activity evaluation by May 3 rd, 2013 CPE credit will be uploaded to CPE Monitor at the end of June
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationManaging the Patient with Atrial Fibrillation
Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationOral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationHow To Compare Warfarin To Dabigatran
Page 1 WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation J E A N N A P P I, P H A R M. D., F C C P, B C P S Accreditation: Pharmacists:
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationCurrent Controversies in Management of Anticoagulation for Atrial Fibrillation
Current Controversies in Management of Anticoagulation for Atrial Fibrillation Cheri Silverstein Fadlon, MD MSCR Assistant Professor of Internal Medicine, COMP Cardiologist, Western Diabetes Institute
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationNew Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011
New Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011 Warfarin Decreases stroke risk by 60-70% Superior to ASA and ASA plus clopidogrel
More informationManagement of Antithrombotics with Procedures. Jordan Weinstein, MD
Management of Antithrombotics with Procedures Jordan Weinstein, MD Presenter Disclosure Information Cardiology Update 2013 I have no relevant financial interest and/or arrangement with industry. Novel
More informationThe New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
More information} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationNIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14
Stroke Prevention in Atrial Fibrillation: Commencing Non- Oral Anticoagulants in GP setting Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts Disclosures NIL Classification
More informationOral Anticoagulation in Older Persons The Next Generation
Oral Anticoagulation in Older Persons The Next Generation Luis Viana B.Sc. Phm., Pharm D (candidate), M.Ed., ACPR, CGP Clinical Consultant Pharmacist, Medical Pharmacies Group Limited Adjunct Clinical
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationPrior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationNew Oral Anticoagulants: Thinning out the competition
New Oral Anticoagulants: Thinning out the competition Ashlee D. Gerfen, Pharm.D. University of Arizona Medical Center PGY2 Critical Care Pharmacy Resident DISCLOSURE I have no financial interest, arrangement,
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationNew Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D.
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationTurn the Beat Around-Remix: Atrial Fibrillation Guidelines-2014 Updates
Turn the Beat Around-Remix: Atrial Fibrillation Guidelines-2014 Updates Brittany Karns, PharmD Alaska Pharmacists Association Annual Conference - 2015 Disclosures I have no actual or potential conflicts
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNew Anticoagulants. Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting. 30-Oct-14
Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting A/Prof Michael Nguyen Fremantle Hospital Access Cardiology General Practice Education Day Oct 2014 ORAL TTP889 Rivaroxaban
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationNHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationNOAC S For Stroke Prevention in. Atrial Fibrillation. Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health
NOAC S For Stroke Prevention in Atrial Fibrillation Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health New Oral Anti Coagulant Formal Definition: Atrial Fibrillation
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationNew Anticoagulants- Dabigatran/Rivaroxaban
New Anticoagulants- Dabigatran/Rivaroxaban JOHN NOVIASKY, PHARMD, BCPS, FNYSCHP CGH AT UPSTATE UNIVERSITY HOSPITAL SYRACUSE NY Objectives Describe the risks and benefits of dabigatran therapy Describe
More informationxaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationManaging Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationAF, Stroke Risk and New Anticoagulants
Carmarthen Cardiac Update Course AF, Stroke Risk and New Anticoagulants Dr Hamsaraj Shetty, B.Sc, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer University Hospital of Wales,Cardiff
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationEliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
More informationAtrial Fibrillation: New Approaches to an Old Friend PETER JESSEL, MD ASSISTANT PROFESSOR
Atrial Fibrillation: New Approaches to an Old Friend PETER JESSEL, MD ASSISTANT PROFESSOR Disclosures None relevant to this presentation Outline Introduction Natural History and Stroke Risk Stroke/Bleeding
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More information